KRAS and cancer: The necessity was illustrated by recent studies where the mutant KRAS in EVs could be detected in a proportion of healthy individuals, patients with non-malignant pancreatic disorders, and 7.4–25 % of PDA patients [58, 59], indicating spontaneous somatic mutations encompassed in EV cargo and disappointing diagnostic performance by unfiltered EVs.